Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117156 · ClinicalTrials.gov registry record · Phase 2
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, Non-Hodgkin and MALT Lymphoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 4
- Study locations
NCT00117156 is a Phase 2 study of Lymphoma, Non-Hodgkin and MALT Lymphoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 26 participants, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00117156, a Phase 2 study of Lymphoma, Non-Hodgkin and MALT Lymphoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness of six cycles of concurrent fludarabine and rituximab in patients with mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma (MZL) or CD5-, CD10-, CD20+ low-grade B cell lymphomas.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Rituximab
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- University of Rochester Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2003-12 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117156
The ClinicalTrials.gov registry entry for NCT00117156 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (93% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 2 interventions - of which Fludarabine is the first listed.
NCT00117156 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00117156 about?
NCT00117156 is a clinical study titled "Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma". The purpose of this study is to determine the effectiveness of six cycles of concurrent fludarabine and rituximab in patients with mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma (MZL) or CD5-, CD10-, CD20+ low-grade B cell lymphomas.
What is the current status of trial NCT00117156?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2003-12. Estimated completion is 2012-01.
What conditions does trial NCT00117156 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, MALT Lymphoma.
What interventions are being tested in trial NCT00117156?
The interventions under investigation include: Fludarabine (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT00117156?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00117156 being conducted?
This trial has 4 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.